The University of Chicago Header Logo

Connection

Mark J. Ratain to Phenylurea Compounds

This is a "connection" page, showing publications Mark J. Ratain has written about Phenylurea Compounds.
Connection Strength

1.153
  1. Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. Br J Cancer. 2018 04; 118(8):1042-1050.
    View in: PubMed
    Score: 0.155
  2. Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther. 2014 Jul; 96(1):27-35.
    View in: PubMed
    Score: 0.118
  3. Estimation of renal cell carcinoma treatment effects from disease progression modeling. Clin Pharmacol Ther. 2013 Apr; 93(4):345-51.
    View in: PubMed
    Score: 0.108
  4. Resampling phase III data to assess phase II trial designs and endpoints. Clin Cancer Res. 2012 Apr 15; 18(8):2309-15.
    View in: PubMed
    Score: 0.101
  5. Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res. 2011 Apr 01; 17(7):1956-63.
    View in: PubMed
    Score: 0.096
  6. A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2010 Mar; 87(3):303-10.
    View in: PubMed
    Score: 0.087
  7. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009 Oct 01; 15(19):6250-7.
    View in: PubMed
    Score: 0.086
  8. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol. 2009 Apr 10; 27(11):1800-5.
    View in: PubMed
    Score: 0.083
  9. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst. 2007 Oct 03; 99(19):1455-61.
    View in: PubMed
    Score: 0.075
  10. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006 Sep 04; 95(5):581-6.
    View in: PubMed
    Score: 0.069
  11. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jun 01; 24(16):2505-12.
    View in: PubMed
    Score: 0.068
  12. Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Oncologist. 2013; 18(8):965-70.
    View in: PubMed
    Score: 0.028
  13. Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Invest New Drugs. 2011 Jun; 29(3):481-8.
    View in: PubMed
    Score: 0.022
  14. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
    View in: PubMed
    Score: 0.020
  15. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics. 2008 Apr 22; 33(2):278-91.
    View in: PubMed
    Score: 0.019
  16. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol. 2006 Nov; 31(6):783-5.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.